Herantis Pharma
2.33 EUR
-2.92 %
4,522 following
Corporate customer
HRTIS
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Investor consensus
-2.92 %
+14.22 %
+17.68 %
+1.75 %
+40.36 %
+54.82 %
-4.51 %
-52.52 %
-76.87 %
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Read moreMarket cap
56.14M EUR
Turnover
39.06K EUR
P/E (adj.) (25e)
-9.34
EV/EBIT (adj.) (25e)
-10.47
P/B (25e)
-43.02
EV/S (25e)
5,769.62
Dividend yield-% (25e)
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5/3
2026
Annual report '25
23/4
2026
General meeting '26
20/8
2026
Interim report Q2'26
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Herantis Pharma Oyj: Managers' Transactions – Aki Prihti
Herantis Pharma Oyj: Managers' Transactions – Aki Prihti
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
